SRTOY OTC
Sartorius Stedim Biotech S.A.
1W: -3.0%
1M: +1.9%
3M: +15.2%
YTD: -1.1%
1Y: +6.6%
3Y: -6.8%
$23.50
-0.23 (-0.97%)
Weekly Expected Move ±6.2%
$21
$22
$24
$25
$26
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$2.9B
+2.5% ▲
5Y CAGR: +8.3%
Gross Profit
$1.3B
+7.1% ▲
5Y CAGR: +5.2%
Operating Income
$527M
+42.3% ▲
5Y CAGR: +2.3%
Net Income
$255M
+45.7% ▲
5Y CAGR: -5.4%
EPS (Diluted)
$0.03
-85.6% ▼
5Y CAGR: -40.9%
EBITDA
$833M
+24.2% ▲
5Y CAGR: +7.9%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.5B | $2.8B | $2.8B | $2.9B |
| YoY Growth | +51.1% | +21.0% | -20.5% | +0.2% | +2.5% |
| Cost of Revenue | $1.3B | $1.7B | $1.5B | $1.6B | $1.6B |
| Gross Profit | $1.6B | $1.8B | $1.2B | $1.2B | $1.3B |
| Gross Margin | 53.8% | 52.5% | 44.4% | 43.4% | 45.3% |
| R&D Expenses | $110M | $132M | $130M | $144M | $0 |
| SG&A Expenses | $532M | $601M | $616M | $648M | $0 |
| Operating Expenses | $670M | $752M | $749M | $836M | $765M |
| Operating Income | $683M | $995M | $484M | $371M | $527M |
| Operating Margin | 23.7% | 28.5% | 17.5% | 13.3% | 18.5% |
| Interest Expense | $10M | $41M | $121M | $159M | $147M |
| Income Before Tax | $647M | $1.1B | $401M | $219M | $358M |
| Tax Expense | $232M | $250M | $89M | $41M | $103M |
| Net Income | $414M | $876M | $310M | $175M | $255M |
| Net Margin | 14.4% | 25.1% | 11.2% | 6.3% | 9.0% |
| EPS (Diluted) | $0.45 | $0.95 | $0.34 | $0.18 | $0.03 |
| EBITDA | $812M | $1.3B | $756M | $670M | $833M |
| Shares Outstanding | 922M | 922M | 922M | 968M | 9.73B |